Cure8 research brief
The study indicates that active inflammation—measured by CDAI and PDAI—drives poorer quality of life in Crohn's disease more than the mere presence of fistulas. That shifts focus toward controlling inflammation to improve daily functioning and wellbeing.
Adults with Crohn's disease (including those with perianal disease), clinicians managing IBD, and caregivers interested in quality-of-life outcomes.
This cross-sectional clinic-based study of 209 adults with Crohn's disease compared patients with and without fistulizing disease using the IBDQ (quality-of-life measure).
Disease activity scores for luminal disease (CDAI) and perianal disease (PDAI) correlated inversely with IBDQ scores, while the simple presence of fistulas, smoking, prior surgery, and biologic exposure were not linked to worse HRQoL.
What this means day to day: For patients and clinicians, the findings emphasize that controlling active inflammation (whether luminal or perianal) is likely more important for improving quality of life than focusing on fistula presence alone.
Discussions about treatment should consider current inflammatory activity when addressing symptoms and quality of life. Study limits and tone: This is a cross-sectional study from a tertiary clinic and uses disease-activity indices and patient-reported IBDQ scores; it reports associations rather than proving cause-and-effect.
Cross-sectional design from a tertiary IBD clinic limits causal inference and generalizability. The study assesses associations using standard activity indices and the IBDQ but does not report longitudinal outcomes.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: Ethical approval was granted by Marmara University, School of Medicine local ethical committee (Approval Date: 08.01.2021 Approval number: 09.2021.31). Informed consent: Informed consent was obtained from all patients.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Identifies features associated with the new international definition of difficult‑to‑treat Crohn’s disease and links DTT status to greater mental fatigue. Biomarker differences (IL‑5, IL‑10) may point to distinct immune...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
